老年患者、女性及少数族裔在瓣膜性心脏病临床试验中的入组情况:系统综述
IMPORTANCE: Inadequate representation of older patients, women, and racial minority individuals in cardiovascular clinical trials limits both the generalizability of trial findings and inclusivity in access to novel therapies and therapeutic strategies.…
要点
- 女性占瓣膜性心脏病试验受试者的41.1%,随时间无显著变化。
- 仅13项(9.4%)试验报告种族/族裔数据,少数族裔代表性无显著时间趋势。
- 入组患者加权平均年龄68.4岁,从2005-2008年的61.9岁非显著增至2017-2020年的72.8岁。
核心结论
- 过去20年,女性和种族及族裔少数个体在北美瓣膜性心脏病临床试验中仍代表性不足。
- 需要进一步改进种族和族裔数据的报告,并解决老年患者、女性和少数族裔入组的障碍。
研究设计与样本
- 纳入标准为入组超过100例成人任何瓣膜性心脏病患者的已发表临床试验。
- 根据发表时间将试验分为4个时间段,分析老年患者、女性和种族及族裔少数个体代表性的时间趋势。
主要发现
- 139项试验中103项(74%)研究主动脉瓣疾病,其余研究二尖瓣疾病。
- 63项试验(45.3%)仅在欧洲入组,24项(17.3%)仅在北美,19项(13.7%)在多个地理区域。
- 女性总体入组比例为41.1%,随时间无显著变化。
- 13项试验(9.4%)报告了受试者的种族和族裔数据,其中美洲印第安人/阿拉斯加原住民、亚洲人、黑人/非洲裔美国人、西班牙裔和夏威夷原住民/太平洋岛民患者在试验层面的代表性范围为0.27%至43.9%。
临床怎么用
- 解读瓣膜性心脏病临床试验结果时,需注意女性和少数族裔代表性不足可能限制结果的外推性。
- 在临床实践中应关注老年、女性和少数族裔患者参与临床试验的机会,促进更包容的入组。
局限性
- 仅9.4%的试验报告了种族和族裔数据,限制了对此类代表性趋势的全面评估。
- 研究仅纳入已发表的试验,可能存在发表偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Inadequate representation of older patients, women, and racial minority individuals in cardiovascular clinical trials limits both the generalizability of trial findings and inclusivity in access to novel therapies and therapeutic strategies. OBJECTIVE: To report on temporal trends in the representation of older patients, women, and racial and ethnic minority individuals in clinical trials studying treatments for valvular heart disease. EVIDENCE REVIEW: All published clinical trials enrolling more than 100 adults with any valvular heart disease published between 2005 and 2020 were included after searches with PubMed and ClinicalTrials.gov. Data on age, sex, race, and ethnicity reported in the included studies were collected. Trials were assigned to 4 time periods based on the publication date, and temporal trends were analyzed in the representation of older patients, women, and racial and ethnic minority individuals. FINDINGS: A total of 139 clinical trials with 51 527 participants were identified. Of these trials, 103 (74%) investigated aortic valve disease and the remainder mitral valve disease. Overall, 63 trials (45.3%) enrolled patients only in Europe, 24 (17.3%) only in North America, and 19 (13.7%) in multiple geographical regions. The weighted mean (SD) age of enrolled patients was 68.4 (11.4) years, increasing nonsignificantly from 61.9 (5.9) years in 2005-2008 to 72.8 (9.6) years in 2017-2020 (P = .09 for trend). The overall proportion of women enrolled in valvular heart disease trials was 41.1%, with no significant changes over time. Data on race and ethnicity of trial participants were reported in 13 trials (9.4%), in which trial-level representation of American Indian/Alaska Native, Asian, Black/African American, Hispanic, and Native Hawaiian/Pacific Islander patients ranged from 0.27% to 43.9%. There were no significant temporal trends noted in the enrollment of racial and ethnic minority populations. The representation of women in clinical trials was positively associated with enrollment rates of older patients and underrepresented racial and ethnic groups. CONCLUSIONS AND RELEVANCE: This review found that over the past 2 decades, women and racial and ethnic minority individuals have remained underrepresented in North American valvular heart disease clinical trials. Further work is needed to improve the reporting of race and ethnicity data and address barriers to trial enrollment for older patients, women, and racial and ethnic minority individuals.
引用
- Reddy KP, Faggioni M, Eberly LA, et al. Enrollment of Older Patients, Women, and Racial and Ethnic Minority Individuals in Valvular Heart Disease Clinical Trials: A Systematic Review. JAMA Cardiol. 2023. PMID: 37494015. doi:10.1001/jamacardio.2023.2098
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。